Overall Fundamental outlook

Business Operations:

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic

Jubilant Pharmova Limited operates as an integrated pharmaceutical company in India, the Americas, Europe, and internationally. It operates through six segments: Radiopharma; Allergy Immunotherapy; Contract Development and Manufacturing Organisation - Sterile Injectables; Generics; Contract Research Development and Manufacturing Organisation; and Proprietary Novel Drugs. The Radiopharma segment offers radiopharmaceuticals products, which are used in the diagnosis and treatment of various diseases, including pulmonary embolism, cancer, coronary artery disease, and others. Its Allergy Immunotherapy segment provides specialised diagnostic devices for skin testing, as well as venom and allergy immunotherapy products. The Contract Development and Manufacturing Organisation - Sterile Injectables segment offers contract manufacturing services for sterile fill and finish injectables, liquids, ointments, creams, and ampoules. Its Generics segment engages in the development, manufacturing, distribution, sale, and marketing of generic formulations for therapeutic areas comprising cardiovascular system, central nervous system, gastrointestinal, antibiotics, and multispecialty. The Contract Research Development and Manufacturing Organisation segment offers drug discovery and development services and active pharmaceutical ingredients. The Proprietary Novel Drugs segment provides patient-focused biopharmaceutical services to address unmet medical needs in oncology and autoimmune diseases. It serves pharmaceutical, biotech, group purchasing organisations, allergists, and hospitals sectors. It sells its products through a network of dealers and distributors. The company was formerly known as Jubilant Life Sciences Limited and changed its name to Jubilant Pharmova Limited in February 2021. The company was incorporated in 1978 and is based in Noida, India.

Revenue projections:

Revenue projections for JUBLPHARMA
Revenue projections for JUBLPHARMA

Investors may be wary of Jubilant Pharmova Limited as its revenues are expected to fall below the prior year's levels. A revenue decrease often leads to concerns about profitability, as it is likely to affect the company's bottom line, prompting investors to take a more cautious approach.

Financial Ratios:

currentRatio 1.619000
forwardPE 18.976377
debtToEquity 50.943000
earningsGrowth -0.224000
revenueGrowth 0.187000
grossMargins 0.680620
operatingMargins 0.097160
trailingEps 25.070000
forwardEps 50.800000

JUBLPHARMA's current ratio of 1.619 means the company has enough liquidity to meet its short-term debt obligations. With sufficient cash reserves and current assets, JUBLPHARMA can comfortably cover its liabilities, reflecting a strong financial outlook.
JUBLPHARMA's Forward PE is in an attractive range, meaning its stock price aligns well with earnings and isn't inflated. This creates room for growth, making it a solid investment opportunity for those looking to benefit from potential price appreciation.
JUBLPHARMA's low growth in both earnings and revenue indicates a likely decrease in profits. This suggests the company may be facing financial challenges, and investors should be cautious about its future performance.
JUBLPHARMA's negative gross and operating margins reflect unprofitability, suggesting the company is unable to generate revenue sufficient to cover its costs. This could indicate deeper financial challenges or declining efficiency.
JUBLPHARMA's forward EPS surpasses its trailing EPS, reflecting expectations of higher profitability in the current year. This suggests that JUBLPHARMA is projected to generate stronger earnings, indicating an optimistic financial outlook compared to the prior year's results.

Price projections:

Price projections for JUBLPHARMA
Price projections for JUBLPHARMA

Jubilant Pharmova Limited's present price relative to projections does not indicate any obvious risks or opportunities. This balanced situation suggests a period of stability, where investors may find it prudent to maintain their current strategies until more information becomes available.

Insider Transactions:

Insider Transactions for JUBLPHARMA
Insider Transactions for JUBLPHARMA


4 separate purchases of JUBLPHARMA stock were made, while market price was at 1068.9750061035156 per share.The period under consideration did not see any buy transactions.Jubilant Pharmova Limited's current price levels are marked by more sells than buys, potentially signaling a price decline. If this trend continues, it may suggest that investors expect the stock to drop further in value.

Recommendation changes over time:

Recommendations trend for JUBLPHARMA
Recommendations trend for JUBLPHARMA


The analysts' mixed ratings for JUBLPHARMA indicate no clear guidance on whether to buy or sell. Investors may need to explore other data points or wait for more concrete market signals before taking any decisive action regarding JUBLPHARMA.